Catherine Schuster

Title: Catherine Schuster: Innovator in Hepatitis C Research

Introduction

Catherine Schuster is a prominent inventor based in Strasbourg, France. She has made significant contributions to the field of medical research, particularly in the development of therapies for hepatitis C virus (HCV) infection. Her innovative work has led to the creation of monoclonal antibodies that play a crucial role in inhibiting HCV entry into susceptible cells.

Latest Patents

Catherine Schuster holds a patent for "Monoclonal anti-claudin 1 antibodies for the inhibition of hepatitis C virus infection." This invention provides monoclonal antibodies that specifically bind to the extracellular domain of human Claudin-1 on the cell surface. By doing so, these antibodies inhibit HCV entry into susceptible cells, thereby preventing HCV infection. The patent also includes hybridoma cell lines that produce such monoclonal antibodies, as well as pharmaceutical compositions that comprise these antibodies. Additionally, methods for treating or preventing HCV infection through the administration of these inventive monoclonal antibodies are described.

Career Highlights

Throughout her career, Catherine has worked with esteemed institutions such as the Institut National de la Santé et de la Recherche Médicale and the Université de Strasbourg. Her research has been pivotal in advancing our understanding of HCV and developing effective treatments.

Collaborations

Catherine has collaborated with notable colleagues, including Thomas Baumert and John Thompson. Their combined expertise has furthered the impact of her research in the field of hepatitis C.

Conclusion

Catherine Schuster's innovative work in developing monoclonal antibodies for hepatitis C represents a significant advancement in medical research. Her contributions continue to influence the fight against HCV infection and highlight the importance of collaboration in scientific discovery.